BidaskClub Upgrades Adaptimmune Therapeutics (ADAP) to “Sell”

Adaptimmune Therapeutics (NASDAQ:ADAP) was upgraded by investment analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued on Saturday.

Other research analysts have also issued reports about the company. Leerink Swann started coverage on Adaptimmune Therapeutics in a research report on Friday. They issued a “buy” rating and a $15.00 target price on the stock. ValuEngine lowered Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. Adaptimmune Therapeutics presently has an average rating of “Hold” and a consensus target price of $11.58.

How to Become a New Pot Stock Millionaire

Adaptimmune Therapeutics (NASDAQ:ADAP) opened at $11.06 on Friday. Adaptimmune Therapeutics has a 52-week low of $3.90 and a 52-week high of $13.41. The firm has a market capitalization of $1,024.94, a PE ratio of -13.33 and a beta of 1.79.

A number of hedge funds have recently modified their holdings of ADAP. Raymond James & Associates acquired a new position in Adaptimmune Therapeutics in the 4th quarter worth about $114,000. Cubist Systematic Strategies LLC acquired a new position in Adaptimmune Therapeutics in the 3rd quarter worth about $182,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Adaptimmune Therapeutics during the 3rd quarter valued at about $199,000. Iguana Healthcare Management LLC acquired a new position in shares of Adaptimmune Therapeutics during the 3rd quarter valued at about $205,000. Finally, Arrowstreet Capital Limited Partnership acquired a new position in shares of Adaptimmune Therapeutics during the 4th quarter valued at about $244,000. 55.58% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The correct version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3270741/bidaskclub-upgrades-adaptimmune-therapeutics-adap-to-sell.html.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Revain Trading Up 22.8% Over Last Week
Revain Trading Up 22.8% Over Last Week
LottoCoin  Price Hits $0.0001 on Exchanges
LottoCoin Price Hits $0.0001 on Exchanges
Aragon One Day Volume Reaches $1.42 Million
Aragon One Day Volume Reaches $1.42 Million
$0.81 Earnings Per Share Expected for Macerich  This Quarter
$0.81 Earnings Per Share Expected for Macerich This Quarter
$1.12 Billion in Sales Expected for Scotts Miracle-Gro  This Quarter
$1.12 Billion in Sales Expected for Scotts Miracle-Gro This Quarter
$114.15 Million in Sales Expected for MarketAxess Holdings, Inc.  This Quarter
$114.15 Million in Sales Expected for MarketAxess Holdings, Inc. This Quarter


© 2006-2018 Ticker Report. Google+.